Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: Prognostic significance and the potential role of allogeneic stem-cell transplantation

Yiming Chen, Jorge Cortes, Zeev Estrov, Stefan Faderl, Wei Qiao, Lynne Abruzzo, Guillermo Garcia-Manero, Sherry Pierce, Xuelin Huang, Partow Kebriaei, Tapan Kadia, Marcos De Lima, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. Patients and Methods: Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. Results: Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15% and 45%, and 3-year OS was 15% and 56%, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). Conclusion: Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.

Original languageEnglish (US)
Pages (from-to)2507-2513
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number18
DOIs
StatePublished - Jun 20 2011
Externally publishedYes

Fingerprint

Remission Induction
Stem Cell Transplantation
Acute Myeloid Leukemia
Chromosome Aberrations
Survival
Recurrence
Cytogenetics
Acute Promyelocytic Leukemia
Induction Chemotherapy
Patient Selection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia : Prognostic significance and the potential role of allogeneic stem-cell transplantation. / Chen, Yiming; Cortes, Jorge; Estrov, Zeev; Faderl, Stefan; Qiao, Wei; Abruzzo, Lynne; Garcia-Manero, Guillermo; Pierce, Sherry; Huang, Xuelin; Kebriaei, Partow; Kadia, Tapan; De Lima, Marcos; Kantarjian, Hagop; Ravandi, Farhad.

In: Journal of Clinical Oncology, Vol. 29, No. 18, 20.06.2011, p. 2507-2513.

Research output: Contribution to journalArticle

Chen, Y, Cortes, J, Estrov, Z, Faderl, S, Qiao, W, Abruzzo, L, Garcia-Manero, G, Pierce, S, Huang, X, Kebriaei, P, Kadia, T, De Lima, M, Kantarjian, H & Ravandi, F 2011, 'Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: Prognostic significance and the potential role of allogeneic stem-cell transplantation', Journal of Clinical Oncology, vol. 29, no. 18, pp. 2507-2513. https://doi.org/10.1200/JCO.2010.34.2873
Chen, Yiming ; Cortes, Jorge ; Estrov, Zeev ; Faderl, Stefan ; Qiao, Wei ; Abruzzo, Lynne ; Garcia-Manero, Guillermo ; Pierce, Sherry ; Huang, Xuelin ; Kebriaei, Partow ; Kadia, Tapan ; De Lima, Marcos ; Kantarjian, Hagop ; Ravandi, Farhad. / Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia : Prognostic significance and the potential role of allogeneic stem-cell transplantation. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 18. pp. 2507-2513.
@article{ac3bfdbcf7154bab808a80c4e6eb8053,
title = "Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: Prognostic significance and the potential role of allogeneic stem-cell transplantation",
abstract = "Purpose: To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. Patients and Methods: Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. Results: Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15{\%} and 45{\%}, and 3-year OS was 15{\%} and 56{\%}, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). Conclusion: Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.",
author = "Yiming Chen and Jorge Cortes and Zeev Estrov and Stefan Faderl and Wei Qiao and Lynne Abruzzo and Guillermo Garcia-Manero and Sherry Pierce and Xuelin Huang and Partow Kebriaei and Tapan Kadia and {De Lima}, Marcos and Hagop Kantarjian and Farhad Ravandi",
year = "2011",
month = "6",
day = "20",
doi = "10.1200/JCO.2010.34.2873",
language = "English (US)",
volume = "29",
pages = "2507--2513",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia

T2 - Prognostic significance and the potential role of allogeneic stem-cell transplantation

AU - Chen, Yiming

AU - Cortes, Jorge

AU - Estrov, Zeev

AU - Faderl, Stefan

AU - Qiao, Wei

AU - Abruzzo, Lynne

AU - Garcia-Manero, Guillermo

AU - Pierce, Sherry

AU - Huang, Xuelin

AU - Kebriaei, Partow

AU - Kadia, Tapan

AU - De Lima, Marcos

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2011/6/20

Y1 - 2011/6/20

N2 - Purpose: To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. Patients and Methods: Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. Results: Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15% and 45%, and 3-year OS was 15% and 56%, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). Conclusion: Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.

AB - Purpose: To determine the prognostic impact of persistent cytogenetic abnormalities at complete remission (CR) on relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) and to examine the potential role of allogeneic stem-cell transplantation (SCT) in this setting. Patients and Methods: Data from 254 adult patients with AML (excluding acute promyelocytic leukemia) who achieved CR after induction chemotherapy on various first-line protocols were examined. Results: Median follow-up for surviving patients was 43 months. Patients with cytogenetic abnormalities at CR (n = 71) had significantly shorter RFS (P = .001) and OS (P < .001) compared with patients with normal cytogenetics at CR (n = 183); 3-year RFS was 15% and 45%, and 3-year OS was 15% and 56%, respectively. Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT in first CR (CR1; n = 15) had better RFS and OS compared to those without SCT (n = 56; P = .04 and .06, respectively). In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predictor for RFS (P < .001) and OS (P = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differences in OS (P = .25) was observed between those who did or did not receive SCT with a trend favoring SCT for RFS (P = .08). Conclusion: Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS. SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.

UR - http://www.scopus.com/inward/record.url?scp=79959323833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959323833&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.34.2873

DO - 10.1200/JCO.2010.34.2873

M3 - Article

C2 - 21555694

AN - SCOPUS:79959323833

VL - 29

SP - 2507

EP - 2513

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -